Merck & Co Could Be Plotting $30bn Bid For Seagen

Regulatory Concerns Remain

 
• By Andrew McConaghie
Seagen
A $30bn plus buy out would also be welcomed by the wider biotech sector, where M&A could help turnaround negative investor sentiment. • Source: Shutterstock

More from Business

More from Scrip